ERBB3 and neoplasm: Patritumab deruxtecan (HER3-DXd) is an antibody–drug conjugate (ADC) with a HER3-directed human monoclonal antibody covalently linked to a topoisomerase I inhibitor payload, effectively delivering cytotoxic agents directly to tumor cells overexpressing HER3 [80].